Skip to main content
. 2011 Dec 22;287(8):5562–5573. doi: 10.1074/jbc.M111.305359

FIGURE 1.

FIGURE 1.

Metabolic features of the FTY720-treated db/db mice. A, fasting glucose levels. ○, FTY720-untreated group; ●, pre-diabetic db/db mice (FG < 126 mg/dl) at 6 weeks old treated with 10 mg/kg of FTY720; and ▴, diabetic db/db mice (FG ≅ 430 mg/dl) at 8–9 weeks old treated with 10 mg/kg of FTY720 (n = 4). I, fasting glucose of mice at the age of 6 to 12 weeks at a daily dosage of 10 mg/kg of FTY720 (n = 20 for the control and FTY720 treated pre-diabetic mice, respectively); II, fasting glucose levels of mice at the age of 12 to 20 weeks at the daily dosage of 10 mg/kg of FTY720 (n = 6 for the control and FTY720 treated mice, respectively); III, fasting glucose levels of mice at the age of 20 to 29 weeks at the weekly dosage of 10 mg/kg of FTY720 (n = 2 for control and FTY720-treated mice, respectively); IV, glucose levels from the mouse without FTY720 treatment after the age of 29 weeks (n = 2 for control and FTY720-treated mice, respectively). B, body weights. The mice were treated as in A and the body weights were measured weekly. C, the distribution of fasting glucose levels after 6 weeks treatment (*, p < 0.0001, one way analysis of variance test). D, fasting serum insulin levels of db/db mice with or without FTY720 treatment (*, p < 0.01). E, glucose tolerance test (1 g/kg 10% glucose) (*, p < 0.01) and F, insulin tolerance test (0.55 units/kg) (*, p < 0.05) were performed after 6 weeks treatment.